<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144742">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02075385</url>
  </required_header>
  <id_info>
    <org_study_id>589/2012</org_study_id>
    <nct_id>NCT02075385</nct_id>
  </id_info>
  <brief_title>Swallowing Intervention During Radiochemotherapy on Head and Neck Cancer</brief_title>
  <acronym>Swallowing-1</acronym>
  <official_title>Randomized Phase II Trial: Swallowing Speech Pathology Intervention During Radiochemotherapy on Patients With Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barretos Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barretos Cancer Hospital</source>
  <oversight_info>
    <authority>Brazil: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      General Objective: To evaluate the swallowing results of speech pathologist rehabilitation
      of advanced oropharynges, larynx and hypopharynx cancer patients during  neoadjuvant
      chemotherapy and radiotherapy concomitant to chemotherapy.

      Methods and Casuistic: Randomized clinical trial phase II. 80 patients with advanced
      oropharynges, larynx and hypopharynx cancer diagnoses from Barretos Cancer Hospital, which
      had the proposal of neoadjuvant chemotherapy followed by radiotherapy combined with
      chemotherapy. Patients are randomized on two groups: control group and speech pathology
      therapy group
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate and compare the swallowing and life quality swallowing  on a group undergoing to
      speech pathology therapy (intervention) and a control group (no intervention).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Swallowing function</measure>
    <time_frame>up to 6 months after concurrent phase.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Self-reporting swallowing questionnaire, clinical swallowing examination and modified barium swallow (MBS), and the MD Anderson Dysphagia Inventory (MDADI).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Head Neck Cancer</condition>
  <condition>Swallowing Disorders</condition>
  <arm_group>
    <arm_group_label>Speech pathology therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre, during and pos-treatment swallowing exercises.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>These patients will not receive speech pathology therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pre, during and pos-treatment swallowing exercises</intervention_name>
    <description>Speech pathology therapy</description>
    <arm_group_label>Speech pathology therapy</arm_group_label>
    <other_name>swallowing pathology therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Head and neck squamous cell carcinoma

          -  Indication for the protocol treatment of neoadjuvant chemotherapy followed by
             radiotherapy concomitant to chemotherapy.

          -  Oropharynges, larynx and hypopharynx advanced cancer (T3 or T4), classified as
             resectable;

          -  18 years old or older;

          -  informed consent signed before any specific procedure

        Exclusion Criteria:

          -  Previous head and neck surgery

          -  Previous radiotherapy or chemotherapy

          -  Previous history of neoplasia, excepted for in situ carcinoma of endometrial
             (uterine) cancer, skin basal cell or squamous cell carcinoma;

          -  Severe laryngeal aspiration during all consistencies swallowing evaluated thought
             videofluoroscopy

          -  Patients with cognitive deficit which could not comprehend the speech pathology
             intervention.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Juliana Portas, MSc</last_name>
    <phone>+55 17 3321 6000</phone>
    <phone_ext>6813</phone_ext>
    <email>julianaportas@globo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luciano de Souza Viana, PhD</last_name>
    <phone>+55 17 3321 6600</phone>
    <phone_ext>6953</phone_ext>
    <email>lsviana1@yahoo.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barretos Cancer Hospital</name>
      <address>
        <city>Barretos</city>
        <state>São Paulo</state>
        <zip>14780400</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliana Portas, MSc</last_name>
      <phone>+55 17 3321 6600</phone>
      <phone_ext>6813</phone_ext>
      <email>julianaportas@globo.com</email>
    </contact>
    <contact_backup>
      <last_name>Luciano de Souza Viana, PhD</last_name>
      <phone>+55 17 33216600</phone>
      <phone_ext>6953</phone_ext>
      <email>lsviana1@yahoo.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Juliana Portas, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>André L Carvalho, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luciano de Souza Viana, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre A Jacinto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>February 28, 2014</lastchanged_date>
  <firstreceived_date>January 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barretos Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Juliana Godoy Portas</investigator_full_name>
    <investigator_title>SLP</investigator_title>
  </responsible_party>
  <keyword>Dysphagia</keyword>
  <keyword>speech language therapy</keyword>
  <keyword>quality of life</keyword>
  <keyword>induction chemotherapy</keyword>
  <keyword>concurrent chemoradiotherapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Deglutition Disorders</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
